{"entity":{"id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","aka":[],"tldr":"A phase 2 trial of Bevacizumab and Nogapendekin alfa inbakicept in glioma & glioblastoma, run by ImmunityBio, Inc., active and no longer recruiting.","summary":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is a phase 2 interventional study registered as NCT06061809 by ImmunityBio, Inc., with 34 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Bevacizumab, PD-L1 t-haNK, N-803 and Tumor Treating Fields (TTFields, 200 kHz).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06061809","url":"https://clinicaltrials.gov/study/NCT06061809"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab","nogapendekin-alfa"],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06061809","phase":"2","setting":"Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and Randomized Phase 2B Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields With or Without PD-L1 t-haNK in Participants With Recurrent or Progressive Glioblastoma","sponsor":"ImmunityBio, Inc.","enrolled":34,"outcomes":[]},"route":"/trials/nct06061809/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}]}}